Abstract
Background:
Effective management of keloid disorder remains elusive, as it often resists monotherapy and demonstrates a high rate of recurrence. Several FDA-approved drugs developed for treating both fibrotic and unrelated conditions have the potential to target key pathways involved in keloid pathogenesis, and some of these have been used for treating keloids with limited efficacy. However, the effects of combinations of these drugs have not been studied systematically. Given the multifactorial nature of keloid formation, we hypothesized that rationally designed drug combinations could produce additive/synergistic anti-fibrotic effects on keloids when administered locally at lower doses, thereby reducing side effects and the development of resistance to treatment.